Hayashi T, Nishioka J, Suzuki K
Department of Molecular Pathobiology, Mie University School of Medicine, Japan.
Biochim Biophys Acta. 1995 Dec 12;1272(3):159-67. doi: 10.1016/0925-4439(95)00081-x.
The congenital abnormal protein S(Tokushima) has Glu substituted for Lys155 in the second epidermal growth factor domain of the protein S molecule (Hayashi T., Nishioka J., Shigekiyo, T. Saito, S. and Suzuki, K. (1994) Blood 83, 683-690). To elucidate the molecular mechanism of the dysfunction of the protein S(Tokushima), a comparative evaluation between the molecular interaction of the abnormal protein S and that of normal protein S with other clotting factors was carried out using recombinant normal protein S (rPSN) and protein S(Tokushima) (rPST) expressed in baby hamster kidney cells. While rPSN and plasma protein S exhibited cofactor activity for activated protein C (APC), rPST did not show this property. rPSN and rPST bound equally to phospholipids and C4b-binding protein fixed on microplate wells. APC bound to rPSN but not to rPST in an assay using immobilized monoclonal anti-protein S antibody. On the other hand, rPSN and plasma protein S inhibited the activity of prothrombinase complex composed of factor Xa and thrombin-stimulated platelets, whereas rPST lacked this inhibitory effect. Assessment of the mechanism by which rPST lacks inhibitory activity on the platelet-prothrombinase complex was also performed. Factor Xa bound to rPSN but not to rPST. Binding to rPSN to biotinylated factor Va in solution phase did not differ significantly from that of rPST. Binding of prothrombin to factor Va in solution phase was not inhibited either by rPSN or rPST. Binding of 4-amidinophenylmethanesulfonyl-factor Xa to factor Va in solution phase increased in the presence of rPSN but not in that of rPST. These findings suggest that the dysfunction of protein S(Tokushima) occurs because it fails to interact with APC and factor Xa. This molecular interaction is required for the expression of the APC cofactor activity and for the inhibition of the prothrombinase complex activity.
先天性异常蛋白S(德岛)在蛋白S分子的第二个表皮生长因子结构域中,其第155位赖氨酸被谷氨酸取代(林田彻、西冈纯、重木敏郎、齐藤修、铃木康(1994年),《血液》83卷,683 - 690页)。为阐明蛋白S(德岛)功能障碍的分子机制,利用在幼仓鼠肾细胞中表达的重组正常蛋白S(rPSN)和蛋白S(德岛)(rPST),对异常蛋白S与正常蛋白S和其他凝血因子之间的分子相互作用进行了比较评估。虽然rPSN和血浆蛋白S对活化蛋白C(APC)表现出辅因子活性,但rPST未表现出此特性。rPSN和rPST与固定在微孔板孔上的磷脂和C4b结合蛋白的结合能力相同。在使用固定化单克隆抗蛋白S抗体的测定中,APC与rPSN结合,但不与rPST结合。另一方面,rPSN和血浆蛋白S抑制由因子Xa和凝血酶刺激的血小板组成的凝血酶原酶复合物的活性,而rPST缺乏这种抑制作用。还对rPST对血小板 - 凝血酶原酶复合物缺乏抑制活性的机制进行了评估。因子Xa与rPSN结合,但不与rPST结合。在溶液相中,rPSN与生物素化因子Va的结合与rPST的结合没有显著差异。rPSN和rPST均未抑制溶液相中凝血酶原与因子Va的结合。在rPSN存在下,溶液相中4 - 脒基苯基甲磺酰 - 因子Xa与因子Va的结合增加,但在rPST存在下未增加。这些发现表明,蛋白S(德岛)功能障碍的发生是因为它无法与APC和因子Xa相互作用。这种分子相互作用对于APC辅因子活性的表达以及凝血酶原酶复合物活性的抑制是必需的。